Phase III clinical study of ART-123 for the treatment of acute exacerbation of idiopathic pulmonary fibrosis
Phase 3
Completed
- Conditions
- Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF)
- Registration Number
- JPRN-jRCT2080223271
- Lead Sponsor
- ASAHI KASEI PHARMA CORPORATIO
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 74
Inclusion Criteria
Main Inclusion Criteria
Patients diagnosed with AE-IPF
Exclusion Criteria
Main Exclusion Criteria
[1]Have intracranial hemorrhage, pulmonary hemorrhage, gastrointestinal bleeding (continued hematemesis, bloody discharge, gastrointestinal ulcer-induced hemorrhage)
[2]Have a history of cerebrovascular disorder (e.g., cerebral hemorrhage or cerebral infarction) within 52 weeks (364 days) before informed consent
[3]Patients who are pregnant or nursing, or who may be pregnant
[4]Have a history of hypersensitivity for investigational product
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method